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1. INTRODUCTION {#tid13371-sec-0005}
===============

The strain of coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) that causes coronavirus disease 2019 (COVID‐19) was detected for the first time in Wuhan, China in December 2019.[^1^](#tid13371-bib-0001){ref-type="ref"} The data on kidney transplant recipients diagnosed with COVID‐19 are limited, and recommendations are based on case series and expert opinion.[^1^](#tid13371-bib-0001){ref-type="ref"}, [^2^](#tid13371-bib-0002){ref-type="ref"}, [^3^](#tid13371-bib-0003){ref-type="ref"}, [^4^](#tid13371-bib-0004){ref-type="ref"}, [^5^](#tid13371-bib-0005){ref-type="ref"}, [^6^](#tid13371-bib-0006){ref-type="ref"}, [^7^](#tid13371-bib-0007){ref-type="ref"} Although uremia and kidney transplantation are not considered a risk factor in COVID‐19, SARS‐CoV‐2 often causes a moderate or severe infection in kidney transplant recipients.[^1^](#tid13371-bib-0001){ref-type="ref"}, [^2^](#tid13371-bib-0002){ref-type="ref"}, [^3^](#tid13371-bib-0003){ref-type="ref"}, [^4^](#tid13371-bib-0004){ref-type="ref"}, [^5^](#tid13371-bib-0005){ref-type="ref"}, [^6^](#tid13371-bib-0006){ref-type="ref"}, [^7^](#tid13371-bib-0007){ref-type="ref"} Lymphopenia, increased inflammatory markers, prothrombin time, and creatine phosphokinase are prognostic factors for COVID‐19.[^8^](#tid13371-bib-0008){ref-type="ref"}, [^9^](#tid13371-bib-0009){ref-type="ref"} Acute kidney injury is also associated with increased morbidity and mortality in COVID‐19 patients.[^9^](#tid13371-bib-0009){ref-type="ref"} However, it is unclear which markers are useful for the monitoring of kidney transplant recipient patients.

Major complaints are fever, dry cough, fatigue, shortness of breath, and diarrhea.[^1^](#tid13371-bib-0001){ref-type="ref"}, [^2^](#tid13371-bib-0002){ref-type="ref"}, [^3^](#tid13371-bib-0003){ref-type="ref"}, [^4^](#tid13371-bib-0004){ref-type="ref"}, [^5^](#tid13371-bib-0005){ref-type="ref"}, [^6^](#tid13371-bib-0006){ref-type="ref"} Pneumonia is the most common manifestation of the infection, characterized by infiltrates in the lung. Cytokine storms also cause organ dysfunction, which may lead to death.[^1^](#tid13371-bib-0001){ref-type="ref"}, [^2^](#tid13371-bib-0002){ref-type="ref"}, [^3^](#tid13371-bib-0003){ref-type="ref"}, [^4^](#tid13371-bib-0004){ref-type="ref"}, [^5^](#tid13371-bib-0005){ref-type="ref"}, [^6^](#tid13371-bib-0006){ref-type="ref"} Diagnosis is usually based on fever, respiratory symptoms, contact history, typical chest radiology, and biochemical findings.[^6^](#tid13371-bib-0006){ref-type="ref"}, [^7^](#tid13371-bib-0007){ref-type="ref"}, [^8^](#tid13371-bib-0008){ref-type="ref"}, [^9^](#tid13371-bib-0009){ref-type="ref"} Positive reverse transcription‐polymerase chain reaction (RT‐PCR) results for COVID‐19 in oral and nasopharyngeal swabs confirm the diagnosis.[^10^](#tid13371-bib-0010){ref-type="ref"}, [^11^](#tid13371-bib-0011){ref-type="ref"} Management of COVID‐19 in kidney transplant recipients should include treatment of the infection, regulation of immunosuppression, and supportive therapy.[^1^](#tid13371-bib-0001){ref-type="ref"}, [^2^](#tid13371-bib-0002){ref-type="ref"}, [^3^](#tid13371-bib-0003){ref-type="ref"}, [^4^](#tid13371-bib-0004){ref-type="ref"}, [^5^](#tid13371-bib-0005){ref-type="ref"}, [^6^](#tid13371-bib-0006){ref-type="ref"}, [^7^](#tid13371-bib-0007){ref-type="ref"} Local transplant centers have created their treatment regimens for COVID‐19 patients. However, there is no consensus on this issue yet. Kidney transplant recipients face several difficulties with this new infectious disease. This study aims to describe our experiences with kidney transplant recipients diagnosed with COVID‐19.

2. MATERIAL AND METHODS {#tid13371-sec-0006}
=======================

2.1. Study population and design {#tid13371-sec-0007}
--------------------------------

Kidney transplant recipients diagnosed with COVID‐19 from five major transplant centers in Istanbul, Turkey, were included in this retrospective cohort study. Initially, 44 kidney transplant recipients diagnosed with COVID‐19 and identified between February 1, 2020 and May 4, 2020 were enrolled. The following exclusion criteria were applied for the study: (a) patients without typical findings (n = 1), (b) loss to follow‐up after diagnosis of COVID‐19 (n = 3). After the diagnosis of COVID‐19, the remaining 40 participants were followed up for a period of at least 15 days or until death (Figure [1](#tid13371-fig-0001){ref-type="fig"}). The Medical Ethics Committee of the Istanbul Faculty of Medicine approved this study.

![Flowchart of the patients in the study. COVID‐19, coronavirus disease 2019](TID-9999-e13371-g001){#tid13371-fig-0001}

The patients were categorized into two groups for analysis. Patients with respiratory failure requiring mechanical ventilation, septic shock, or multiple organ dysfunction were defined as having severe pneumonia. All other cases were classified as having moderate pneumonia.

2.2. Data collection {#tid13371-sec-0008}
--------------------

The demographics, clinical data, comorbidities, laboratory and radiological results, data on anti‐viral and anti‐cytokine treatments, and management of immunosuppression were extracted from electronic medical records. Nasal and oropharyngeal swabs were collected and tested for SARS‐CoV‐2 RNA with RT‐PCR assay. All patients underwent non‐contrast chest computerized tomography (CT) scanning in the supine position during end‐inspiration. All cases demonstrated early or progressive radiographic deterioration on CT at the initial admission.

2.3. Patient management {#tid13371-sec-0009}
-----------------------

The COVID‐19 diagnosis was based on contact history, symptoms, laboratory, and radiological findings. A positive RT‐PCR test was used to confirm the diagnosis. Indications for hospitalization were moderate, severe pneumonia and cytokine release syndrome (persistent fever, blood lymphocyte count \<800/mm^3^, serum C‐reactive protein \> 40 mg/L, aspartate aminotransferase \>45 IU/L, ferritin \> 500 ng/mL, D‐dimer \> 1000 ng/mL, and triglyceride \> 150 mg/dL). Criteria for admission to the intensive care unit (ICU) were a partial pressure of arterial oxygen and inspiratory oxygen fraction (PaO~2~/FiO~2~) ratio less than 300, oxygen saturation under 90% and PaO~2~ below 70 mm Hg despite 5 L/min oxygen therapy, and/or persistent hypotension (systolic blood pressure \< 90 mm Hg or mean arterial pressure \< 65 mm Hg).

2.4. Anti‐viral and cytokine‐targeted therapy {#tid13371-sec-0010}
---------------------------------------------

All of the patients were initially treated with hydroxychloroquine (400 mg BID for the first day, and then 200 mg BID for four days; oral) and azithromycin (500 mg QD for the first day, and then 250 mg QD for four days; oral). Tocilizumab (400 mg QD for two days; intravenous) or anakinra (100 mg QD for 7‐14 days or until hospital discharge; subcutaneous) were used in the treatment of cytokine release syndrome. Resistant cases were treated with favipiravir (1600 mg BID for the first day, and then 600 mg BID for four days; oral). Antibiotic therapy was administered based on the infection specialist\'s decision in the presence of confirmed or suspected invasive bacterial infection. The patients were also monitored for adverse drug reactions during the hospital stay. The QT interval of all patients was regularly monitored.

2.5. Adjustment of immunosuppressive regimen {#tid13371-sec-0011}
--------------------------------------------

A standard protocol was used to manage immunosuppression, anti‐viral, and cytokine‐targeted therapy (Figure [2](#tid13371-fig-0002){ref-type="fig"}). Antimetabolites (mycophenolate derivatives and azathioprine) were discontinued in all cases. Steroid doses were increased to a stress dose in the early period and then continued at a maintenance dose. Calcineurin doses were halved in patients with a stable clinic course and were discontinued in hypoxemic patients. The calcineurin and mammalian target of rapamycin (mTOR) levels were also monitored twice a week.

![Treatment scheme for COVID‐19 in kidney transplant recipients. AZM, azithromycin; CNI, calcineurin inhibitors; COVID‐19, coronavirus disease 2019; CSS, cytokine storm syndrome; HCQ, hydroxychloroquine; ICU, intensive care unit; KTR, kidney transplant recipient; RT‐PCR, reverse transcription‐polymerase chain reaction](TID-9999-e13371-g002){#tid13371-fig-0002}

2.6. Anticoagulation and oxygen treatment {#tid13371-sec-0012}
-----------------------------------------

Low‐molecular‐weight heparin was used in all patients unless there were contraindications. Doses were adjusted according to the patients\' risk of bleeding and coagulation. Oxygen treatment was provided to patients whose oxygen saturation was below 92% via a nasal cannula, and with a mask with a reservoir, if this was insufficient. If respiratory failure continued despite these treatments, mechanical ventilation was provided after non‐invasive ventilation.

2.7. Outcomes {#tid13371-sec-0013}
-------------

The primary endpoint was all‐cause mortality. The secondary endpoints were acute kidney injury, the average length of hospital stay, admission to intensive care, and mechanical ventilation.

2.8. Statistical analysis {#tid13371-sec-0014}
-------------------------

Categorical variables were summarized with counts and percentages. Quantitative variables were summarized with means and standard deviations or medians and interquartile range statistics, where appropriate. The chi‐square and Fisher\'s exact tests were performed for qualitative variables, whereas the Mann‐Whitney *U* test was used for quantitative variables with the non‐parametric distribution. Logistic regression analysis was used to identify patient loss and the associated risk in terms of odds ratio and 95% confidence intervals. Variables were selected by backward elimination using likelihood ratio tests. A *P*‐value of \<.05 was considered significant.

3. RESULTS {#tid13371-sec-0015}
==========

3.1. Demographics and clinical characteristics {#tid13371-sec-0016}
----------------------------------------------

Forty patients (20 female) were reviewed retrospectively over a median follow‐up period of 32 days (interquartile range, 14‐51 days) after being diagnosed with COVID‐19. The demographic characteristics and immunosuppression regimen of patients according to their groups, are shown in Table [1](#tid13371-tbl-0001){ref-type="table"}. Only one patient (3%) in the moderate pneumonia group was followed up in the outpatient clinic, and all other patients were hospitalized. No differences were observed between the groups in terms of age, gender, post‐transplant follow‐up time, etiology of chronic kidney disease (CKD), donor type, and comorbidities (Table [1](#tid13371-tbl-0001){ref-type="table"}). Moderate pneumonia was detected in 33 (82.5%) kidney transplant recipients and severe pneumonia in 7 (17.5%). The frequency of previous induction (n = 18 \[54.6%\] and n = 7 \[100%\]; *P* = .016, respectively) and rejection therapy (n = 4 \[12.1%\] and n = 3 \[42.9%\]; *P* = .023, respectively) was significantly higher in the group with severe pneumonia compared to the moderate pneumonia group. Although no significant difference was found between the groups in terms of tacrolimus usage (n = 25 \[75.8%\] and n = 6 \[85.7%\]; *P* = .525, respectively), none of the patients using cyclosporine A (n = 5 \[15.2%\] and n = 0 \[0%\]; *P* \< .001, respectively), developed severe pneumonia.

###### 

Patients\' demographic characteristics and immunosuppression regimen

                                                      All patients (n = 40)   Moderate pneumonia (n = 33)   Severe pneumonia (n = 7)   *P*‐value
  --------------------------------------------------- ----------------------- ----------------------------- -------------------------- ------------
  Demographic characteristics                                                                                                          
  Age (mean ± SD, y)                                  44.9 ± 14.8             43.3 ± 14.9                   49.3 ± 14.8                .388
  Sex (n, %)                                                                                                                           
  Male                                                20 (50%)                17 (51.5%)                    3 (42.9%)                  **.05**
  Female                                              20 (50%)                16 (48.5%)                    4 (57.1%)                  
  Post‐transplant follow‐up (Median‐IQR 25‐75, mo)    74.5 (31.5‐128.3)       77 (29.5‐133)                 74 (49‐108)                .746
  Etiology of CKD (n, %)                                                                                                               
  Hypertensive nephropathy                            4 (10%)                 4 (12.1%)                     0                          .416
  Diabetic nephropathy                                2 (5%)                  1 (3%)                        1 (14.3%)                  
  Chronic glomerulonephritis                          13 (32.5%)              10 (30.3%)                    3 (42.9%)                  
  Other                                               6 (15%)                 6 (18.2%)                     0                          
  Unknown                                             15 (37.5%)              12 (36.4%)                    3 (42.9%)                  
  Comorbidities (n, %)                                                                                                                 
  Pre‐existing lung disease                           3 (7.5%)                3 (9.1%)                      0                          .552
  Previous heart disease                              3 (7.5%)                3 (9.1%)                      0                          .552
  Chronic hypertension                                26 (65%)                21 (63.6%)                    5 (71.4%)                  .529
  Usage of RAS blockage                               18 (45%)                15 (45.5%)                    3 (42.9%)                  .617
  Type of donor (n, %)                                                                                                                 
  Living                                              35 (87.5%)              30 (90.9%)                    5 (71.4%)                  .204
  Deceased                                            5 (12.5%)               3 (9.1%)                      2 (28.6%)                  
  Immunosuppression                                                                                                                    
  Induction therapy (n, %)                                                                                                             
  ATLG                                                22 (55%)                15 (45.5%)                    7 (100%)                   **.016**
  Basiliximab                                         3 (7.5%)                3 (9.1%)                      0                          
  Anti‐rejection therapy (n, %)                       7 (17.5%)               4 (12.1%)                     3 (42.9%)                  **.023**
  Maintenance immunosuppression at admission (n, %)                                                                                    
  Tacrolimus                                          31 (77.5%)              25 (75.8%)                    6 (85.7%)                  .525
  Cyclosporine A                                      5 (12.5%)               5 (15.2%)                     0                          **\<.001**
  mTOR inhibitors                                     4 (10%)                 3 (9.1%)                      1 (14.3%)                  .502
  Mycophenolate derivatives                           36 (90%)                29 (87.9%)                    7 (100%)                   .624
  Steroids                                            40 (100%)               33 (100%)                     7 (100%)                   1

*P*‐values compared moderate pneumonia and severe pneumonia, obtained from the chi‐square test, Fisher\'s exact test, or Mann‐Whitney *U* test.

*P*‐values in bold showed statistically significant differences.

Abbreviations: ATLG, anti‐T‐lymphocyte globulin; CKD, chronic kidney disease; mTOR, mammalian target of rapamycin.
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3.2. Clinical presentations and laboratory results {#tid13371-sec-0017}
--------------------------------------------------

Cough (n = 30 \[75%\]), fever (n = 25 \[62.5%\]), and dyspnea (n = 21 \[52.5%\]) were the most frequent symptoms in all patients. Although all serum acute phase reactants were more increased in patients with severe pneumonia compared to the other group (Table [2](#tid13371-tbl-0002){ref-type="table"}), a significant difference was also found in the serum lactate dehydrogenase (249 \[interquartile range, 174‐340\] and 559 \[interquartile range, 275‐666\]; *P* = .048, respectively) and alanine aminotransferase values only (15 \[interquartile range, 8‐23\] and 27 \[interquartile range, 23‐39\]; *P* = .015, respectively). The frequency of graft dysfunction was similar between the groups (n = 12 \[36.4%\] and n = 2 \[28.6%\]; *P* = .615, respectively). None of the patients developed graft loss during follow‐up (Table [2](#tid13371-tbl-0002){ref-type="table"}).

###### 

Patients\' clinical characteristics and laboratory results

+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
|                                                   | All patients (n = 40) | Moderate pneumonia (n = 33) | Severe pneumonia (n = 7) | *P*‐value |
+===================================================+=======================+=============================+==========================+===========+
| Time                                              |                       |                             |                          |           |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Post‐infection follow‐up (Median‐IQR 25‐75, d)    | 32 (23‐44)            | 31 (22‐41)                  | 44 (41‐51)               | .087      |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Duration of hospitalization (Median‐IQR 25‐75, d) | 9 (5‐12)              | 7 (4‐12)                    | 13 (11‐28)               | **.002**  |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Clinical characteristics                          |                       |                             |                          |           |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Contact history (n, %)                            | 20 (50%)              | 15 (45.5%)                  | 5 (71.4%)                | .204      |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Presentation symptoms (n, %)                      |                       |                             |                          |           |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Fever                                             | 25 (62.5%)            | 19 (57.6%)                  | 6 (85.7%)                | .168      |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Cough                                             | 30 (75%)              | 25 (75.8%)                  | 5 (71.4%)                | .575      |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Dyspnea                                           | 21 (52.5%)            | 14 (42.4%)                  | 7 (100%)                 | **.006**  |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Diarrhea                                          | 10 (25%)              | 9 (27.3%)                   | 1 (14.2%)                | .51       |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Initial examination findings (Median‐IQR 25‐75)   |                       |                             |                          |           |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Pulse rate (/min)                                 | 88 (79‐98)            | 84 (78‐98)                  | 94 (86‐101)              | .344      |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| SpO~2~ value (%)                                  | 96 (93‐98)            | 96 (94‐98)                  | 90 (88‐96)               | **.007**  |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Respiratory rate (/min)                           | 18 (16‐24)            | 18 (16‐23)                  | 22 (18‐26)               | .646      |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Blood pressure (Median‐IQR 25‐75, mm Hg)          |                       |                             |                          |           |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Systolic                                          | 120 (114‐135)         | 120 (110‐140)               | 120 (118‐133)            | .5        |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Diastolic                                         | 70 (68‐80)            | 70 (65‐80)                  | 80 (69‐83)               | .475      |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Laboratory results                                |                       |                             |                          |           |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Laboratory results at admission                   |                       |                             |                          |           |
|                                                   |                       |                             |                          |           |
| (Median‐IQR 25‐75)                                |                       |                             |                          |           |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Serum creatinine (mg/dL)                          | 1.6 (1.2‐2.2)         | 1.7 (1.4‐2.4)               | 1.2 (1.1‐2.1)            | .288      |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Leucocyte count (/mm^3^)                          | 5150 (4013‐7035)      | 4635 (3975‐7110)            | 6250 (4190‐6825)         | .75       |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Lymphocyte count (/mm^3^)                         | 725 (503‐1080)        | 755 (498‐1100)              | 660 (420‐1035)           | .566      |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Hemoglobin count (g/dL)                           | 11.2 (9.7‐12.7)       | 11.1 (9.6‐12.8)             | 11.3 (9.2‐12.5)          | .865      |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Platelet count (/mm^3^)                           | 192 (154‐238)         | 192 (160‐237)               | 192 (138‐266)            | .932      |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Serum CRP levels (mg/L)                           | 45 (24‐88)            | 44 (15‐78)                  | 66 (35‐167)              | .235      |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Serum ALT levels (IU/L)                           | 16 (10‐27)            | 15 (8‐23)                   | 27 (23‐39)               | **.015**  |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Serum AST levels (IU/L)                           | 23 (15‐34)            | 22 (13‐30)                  | 34 (20‐43)               | .064      |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Serum LDH levels (IU/L)                           | 257 (198‐370)         | 249 (174‐340)               | 559 (275‐666)            | **.048**  |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Serum D‐dimer levels (ng/mL)                      | 720 (510‐1374)        | 665 (505‐1469)              | 1075 (598‐1343)          | .593      |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Serum ferritin levels (ng/mL)                     | 358 (173‐992)         | 319 (161‐871)               | 634 (264‐1906)           | .329      |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Serum procalcitonin (ng/mL)                       | 0.2 (0.1‐0.3)         | 0.2 (0.1‐0.3)               | 0.4 (0.2‐1.1)            | .13       |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+
| Graft dysfunction at admission (n, %)             | 14 (35%)              | 12 (36.4%)                  | 2 (28.6%)                | .615      |
+---------------------------------------------------+-----------------------+-----------------------------+--------------------------+-----------+

*P*‐values compared moderate pneumonia and severe pneumonia, obtained from the chi‐square test, Fisher\'s exact test, or Mann‐Whitney *U* test.

*P*‐values in bold showed statistically significant differences.

Abbreviations: SpO2 = blood oxygen saturation levels; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C‐reactive protein; LDH, lactate dehydrogenase.
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3.3. Outcomes {#tid13371-sec-0018}
-------------

Five patients (12.5%) died during follow‐up in the ICU. Two patients died due to respiratory failure, and three patients due to multiorgan failure associated with cytokine release syndrome. The dosage of calcineurin inhibitors was halved in 23 (69.7%) patients with moderate pneumonia and two (28.6%) with severe pneumonia. Eighteen patients (45%) were treated with favipiravir and eight patients (20%) with cytokine‐targeted therapy. Anti‐viral (n = 12 \[36.4%\] and n = 6 \[85.7%\]; *P* = .024, respectively) and cytokine‐targeted therapy (n = 5 \[15.2%\] and n = 3 \[42.9%\]; *P* = .024, respectively) were more widely used in the severe pneumonia group. Twenty‐four patients (60%) received antibiotics. Six of the seven patients (85.7%) with severe pneumonia who were followed up in the ICU received mechanical ventilation (Table [3](#tid13371-tbl-0003){ref-type="table"}). No arrhythmia or other adverse events were detected during follow‐up. No significant pharmacological interaction was observed between the drugs and calcineurin inhibitors during the follow‐up. No significant differences were observed in the calcineurin levels.

###### 

Patients\' treatment regimens and outcomes

                                        All patient s (n = 40)   Moderate pneumonia (n = 33)   Severe pneumonia (n = 7)   *P*‐value
  ------------------------------------- ------------------------ ----------------------------- -------------------------- ------------
  Treatment modalities and outcomes                                                                                       
  Withdrawal of IS agent (n, %)                                                                                           
  Calcineurin inhibitors                11 (27.5%)               7 (21.2%)                     4 (57.1%)                  **.**075
  Antimetabolites                       40 (100%)                33 (100%)                     7 (100%)                   1
  mTOR inhibitors                       4 (10%)                  3 (9.1%)                      1 (14.3%)                  1
  Treatment of infection (n, %)                                                                                           
  Favipiravir                           18 (45%)                 12 (36.4%)                    6 (85.7%)                  **.024**
  Anti‐cytokine agents (n, %)                                                                                             
  Tocilizumab                           5 (12.5%)                2 (6.1%)                      3 (42.9%)                  **.024**
  Anakinra                              3 (7.5%)                 3 (9.1%)                      0                          
  Antibiotics (n, %)                    24 (60%)                 21 (63.6%)                    3 (42.9%)                  .273
  Ventilation devices (n, %)                                                                                              
  Nasal cannula                         37 (92.5%)               30 (90.9%)                    7 (100%)                   **0.407**
  Non‐invasive ventilation              4 (10%)                  1 (3%)                        3 (42.9%)                  **.013**
  Mechanical ventilation                6 (15%)                  0                             6 (85.7%)                  **\<.001**
  Follow‐up in intensive care unit      7 (17.5%)                0                             7 (100%)                   **\<.001**
  Number of patient fatalities (n, %)   5 (12.5%)                0                             5 (71.4%)                  **\<.001**

*P*‐values compared moderate pneumonia and severe pneumonia, obtained from the chi‐square test, Fisher\'s exact test, or Mann‐Whitney *U* test.

*P*‐values in bold showed statistically significant differences.

Abbreviations: IS, immunosuppression; mTOR, mammalian target of rapamycin.
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Multivariate logistic regression analysis also revealed that previous anti‐rejection therapy (9.75 \[95% CI, 1.223 to 77.724; *P* = .032\]) was the independent predictor for mortality (Table [4](#tid13371-tbl-0004){ref-type="table"}). The use of cyclosporine (0.077 \[95% CI, 0.018‐0.324; *P *≤ .001\], respectively) was associated with a lower incidence of death.

###### 

Logistic regression analysis of mortality risk factors for kidney transplant recipients

                                       Univariate analysis   Multivariate analysis                                       
  ------------------------------------ --------------------- ----------------------- ------------ ------- -------------- ------------
  Age                                  0.992                 0.931‐1.058             .812                                
  Male sex                             1.588                 0.236‐10.704            .635                                
  Post‐transplant time                 0.996                 0.98‐1.012              .638                                
  Deceased donor                       0.516                 0.046‐5.84              .593                                
  ATLG usage as an induction therapy   1.83                  0.522‐6.413             .345                                
  Usage of cyclosporine                0.167                 0.065‐0.43              **\<.001**   0.077   0.018‐0.324    **\<.001**
  Anti‐rejection therapy               11.625                1.467‐92.139            **.02**      9.75    1.223‐77.724   **.032**
  SpO~2~ value                         0.915                 0.723‐1.158             .46                                 
  Serum LDH levels                     1.006                 0.098‐1.014             .052                                
  Serum ALT levels                     1.009                 0.974‐1.045             .622                                
  Graft dysfunction at admission       0.538                 0.051‐5.74              .608                                
  CNI withdrawal after admission       0.198                 0.028‐1.396             .104                                
  Anti‐viral treatment                 6                     0.606‐59.444            .126                                
  Antibiotics                          0.13                  0.013‐1.301             .087                                
  Anti‐cytokine agents                 0.31                  0.042‐2.278             .25                                 

*P*‐values in bold showed statistically significant differences.

Abbreviations: ALT, alanine aminotransferase; ATLG, anti‐T‐lymphocyte globulin; CNI, calcineurin inhibitors; LDH, lactate dehydrogenase; RT‐PCR, reverse transcription‐polymerase chain reaction; SpO~2~, blood oxygen saturation levels.
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4. DISCUSSION {#tid13371-sec-0019}
=============

COVID‐19 is a life‐threatening respiratory disease that has affected countries all over the world. SARS‐CoV‐2 has been seen to often lead to lower respiratory tract infections requiring hospitalization in kidney transplant recipients. In this study, we analyzed 40 kidney transplant recipients diagnosed with COVID‐19 over a median follow‐up period of 32 days. All of our patients had moderate to severe pneumonia. All patients except one were followed up in the hospital or ICU. 87.5% of our patients had received kidney transplants from living donors. Severe pneumonia was common in patients receiving anti‐rejection and induction therapy. Hypoxemia was more common in patients with severe pneumonia, and the serum lactate dehydrogenase and alanine aminotransferase values were higher in this group. Five patients died in intensive care during follow‐up. Both cytokine‐targeted therapy and favipiravir were used more commonly in the group with severe pneumonia. Multivariate logistic regression analysis demonstrated that the use of cyclosporine was associated with a lower incidence of death. Conversely, rejection therapy was identified as a risk factor for death.

Early mortality in kidney transplant recipients varies at a rate of 6%‐25%.[^1^](#tid13371-bib-0001){ref-type="ref"}, [^2^](#tid13371-bib-0002){ref-type="ref"}, [^3^](#tid13371-bib-0003){ref-type="ref"}, [^4^](#tid13371-bib-0004){ref-type="ref"}, [^5^](#tid13371-bib-0005){ref-type="ref"}, [^6^](#tid13371-bib-0006){ref-type="ref"} In our study, almost all of our patients were hospitalized with moderate or severe pneumonia. Five patients died during the follow‐up. The lower mortality rate compared with the data from Italy and the USA may be due to several reasons.[^2^](#tid13371-bib-0002){ref-type="ref"}, [^4^](#tid13371-bib-0004){ref-type="ref"} The low average age and lower comorbidity rate of the study population could be important reasons. While the average age of our cohort was 44.9, it was reported as being 60 in Akalin et al\'s series.[^2^](#tid13371-bib-0002){ref-type="ref"} In the same study, the frequency of hypertension and diabetes mellitus were 94% and 69%, respectively. We found these frequencies to be 65% and 5%, respectively. Another critical point is that our study group consisted of mostly living‐related transplantation patients. This condition may have led to lower induction use and low cumulative immunosuppression, which may have led to a low mortality rate.

Similarly to our study, previous studies have demonstrated that induction and anti‐rejection therapy may be a risk factor for mortality in COVID‐19.[^1^](#tid13371-bib-0001){ref-type="ref"}, [^2^](#tid13371-bib-0002){ref-type="ref"}, [^3^](#tid13371-bib-0003){ref-type="ref"}, [^4^](#tid13371-bib-0004){ref-type="ref"}, [^5^](#tid13371-bib-0005){ref-type="ref"}, [^6^](#tid13371-bib-0006){ref-type="ref"} For this reason, it may be a rational approach to avoid induction therapy in patients with low immunological risk during the COVID‐19 pandemic. Clinicians should be aware that potent immunosuppressants, especially anti‐T‐lymphocyte globulin, are very risky.

The number of coronavirus infections is increasing in kidney transplant recipients. However, the optimal immunosuppression strategy during the COVID‐19 pandemic remains unknown. The ideal approach for continued immunosuppression treatment is to protect against graft rejection and to maintain enough immunity to prevent overwhelming infection. By our protocol, antimetabolites were discontinued initially, calcineurin doses were halved, and steroids were increased in the stress dose. No permanent kidney damage or graft loss occurred during follow‐up. However, the majority of patients in our study population had low immunological risk. Recent studies have demonstrated that acute kidney injury occurs in 21%‐30% of kidney transplant recipients.[^2^](#tid13371-bib-0002){ref-type="ref"}, [^3^](#tid13371-bib-0003){ref-type="ref"} Therefore, discontinuation of all immunosuppression in patients with high immunological risk should be treated with caution. It could cause rejection and graft loss.

Concurrently, cyclosporine A inhibits the replication of coronaviruses and may be an effective treatment in patients with macrophage activation syndrome.[^12^](#tid13371-bib-0012){ref-type="ref"}, [^13^](#tid13371-bib-0013){ref-type="ref"}, [^14^](#tid13371-bib-0014){ref-type="ref"} In our study, the use of cyclosporine was associated with a lower incidence of death. Hence, it would be beneficial to investigate the role of cyclosporine A in the treatment of this disease.

The use of tocilizumab has been reported in the treatment of cytokine release syndrome triggered by COVID‐19.[^2^](#tid13371-bib-0002){ref-type="ref"}, [^4^](#tid13371-bib-0004){ref-type="ref"}, [^5^](#tid13371-bib-0005){ref-type="ref"} Previous studies have also demonstrated the use of lopinavir‐ritonavir and darunavir‐ritonavir in the treatment of COVID‐19. Drug‐drug interaction between anti‐viral drugs and calcineurin inhibitors has been reported in these studies.[^2^](#tid13371-bib-0002){ref-type="ref"}, [^4^](#tid13371-bib-0004){ref-type="ref"}, [^5^](#tid13371-bib-0005){ref-type="ref"} To the best of our knowledge, the use of favipiravir and anakinra in the treatment of COVID‐19 in kidney transplant recipients has not been previously reported. Our study was not conducted to investigate the effectiveness of these drugs. However, unlike other anti‐virals, favipiravir does not exhibit drug--drug interaction between calcineurin inhibitors. Therefore, regular monitoring of the calcineurin inhibitor levels may not be necessary when using favipiravir. We did not encounter any problems with the CNI levels in patients taking favipiravir.

With regard to the hydroxychloroquine treatment given to all patients, we did not observe any side effects such as arrhythmia, QT prolongation, nausea, diarrhea, retinal toxicity, cutaneous rash, or hypoglycemia.

Our retrospective study has many limitations; the sample size is small, and the follow‐up period is short. Other limitations were that there is no control group and PCR samples were only collected from patients with moderate or severe symptoms rather than all patients. The many restrictions and prejudices involved have meant that we are unable to draw definitive conclusions from these experiences. Hence, our findings are preliminary and will need to be confirmed in large‐scale prospective cohort studies with longer follow‐up. The use of a standard treatment model may be considered as the strength of the study.

In conclusion, COVID‐19 has been seen to more commonly cause moderate or severe pneumonia in kidney transplant recipients, possibly due to immunosuppressive therapy. The mortality rate of these patients is higher than that of the general population; therefore, immunosuppression should be carefully reduced in these patients. No anti‐viral and cytokine‐targeted therapy have been approved yet for the treatment of COVID‐19. Hence, all drugs should be used with caution in these patients. Induction therapy with lymphocyte‐depleting agents should be carefully avoided in kidney transplant recipients during the pandemic period.
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I would like to mention those healthcare professionals who have been victims of COVID‐19 in Turkey. In Turkey, 7428 health workers have been infected and some of these individuals have died from the disease. In particular, I wish to commemorate our teacher, Professor Murat Dilmener, and Cemil Tasçıoğlu, both of whom died of COVID‐19. Both spent many years working as clinicians and teachers at Istanbul University. We remember them with respect and appreciation.
